QuiaPEG Pharmaceuticals operates in medical technology. The company has developed a technological platform that is used to improve and develop existing pharmaceuticals. The technology is based on what is known as PEGylation, a technique that connects water-soluble polymers with the pharmaceuticals and is used to improve various characteristics in the biopharmaceuticals in regards to stability and resistance.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio Vitos Norge AS | 15,61 | 15,61 | 2024-09-26 |
| Bo Nordlander | 11,63 | 11,63 | 2024-09-26 |
| Sodra Langudden Forvaltning AB | 7,18 | 7,18 | 2024-09-26 |
| Kjell Jonsson | 3,76 | 3,76 | 2024-09-26 |
| Gunnela Kristina M Blomqvist | 2,04 | 2,04 | 2024-09-26 |
| Michael Fogelberg med familj | 1,99 | 1,99 | 2024-09-26 |
| Olov Orlander | 1,59 | 1,59 | 2024-09-26 |
| Sami Sinno | 1,26 | 1,26 | 2024-09-26 |
| Anders Gahne | 1,07 | 1,07 | 2024-09-26 |
| Olle Svedåker | 1,02 | 1,02 | 2024-09-26 |
